LOS ANGELES--(BUSINESS WIRE)--
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC)
announced that the US Patent and Trademark Office (USPTO) has issued a
key patent application covering ICT-121, an immunotherapeutic vaccine
targeting CD133, an important cancer stem cell marker that is commonly
overexpressed on a broad range of solid tumors. The patent includes
claims covering composition of matter as well as methods of use.
Specifically, the claims encompass immunogens comprising a CD133 epitope
and variants thereof as well as methods of using such immunogens in
immunization and to elicit cytotoxic T lymphocyte responses that are
specific for tumor cells expressing HLA-A2.
"This issued patent provides significant protection for ICT-121 with
what we believe are broad claims, and is an important addition to
ImmunoCellular's intellectual property estate for our cancer vaccines
and monoclonal antibodies," said Andrew Gengos, ImmunoCellular Chief
Executive Officer. "We believe that our growing IP asset strengthens our
leadership position in the cancer immunotherapy field, and we look
forward to continuing to advance our cancer immunotherapy product
candidates through the development process."
ICT-121 is a dendritic cell vaccine. CD133 is highly expressed on cancer
stem cells on most solid tumors, including brain, colon, non-small cell
lung, melanoma, pancreatic and breast cancers. ImmunoCellular plans to
support an investigator-sponsored, 20-patient phase I trial in recurrent
glioblastoma at Cedars-Sinai Medical Center.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage
company that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular is conducting a phase II trial
of its lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell
vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting
ovarian cancer antigens and cancer stem cells. To learn more about
ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular
This press release contains certain forward-looking statements that are
subject to a number of risks and uncertainties, including the risk that
ICT-107 can be further successfully developed or commercialized and the
timing of the initiation of the ICT-121 phase I clinical trial.
Additional risks and uncertainties are described in IMUC's most recently
filed quarterly report on Form 10-Q and annual report on Form 10-K.
Except as required by law, IMUC undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
Jane Green, 415-348-0010
Source: ImmunoCellular Therapeutics, Ltd.
News Provided by Acquire Media